Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

IBD-associated SpA · Joints, Spine & Gut

When the Bowel and Joints Respond Differently

For patients · Chapter 7

Evidence reviewed as of October 5, 2026

On this page
  1. Bowel and joint disease can follow different courses
  2. Persistent pain and persistent inflammation are not identical
  3. New diarrhea is not automatically an IBD flare
  4. What tests can help clarify the mismatch?
  5. Never worked, partly worked, or stopped working?
  6. Symptoms after a medicine change need a careful timeline
  7. Leave with a decision and a follow-up point
  8. Sources and further reading

Your bowel symptoms have improved, but your back still wakes you at night. Or your joints feel much better while diarrhea returns. This mismatch deserves a fresh assessment. It does not, by itself, prove that a treatment has failed, caused harm, or needs to be stopped.

Bowel and joint disease can follow different courses

Some peripheral joint inflammation improves as bowel inflammation settles. Other patterns, particularly axial SpA, can remain active when the bowel is doing well. A treatment can also work better in one organ than another. This is why the gastroenterologist and rheumatologist should judge the two conditions separately before agreeing on a shared plan. [1]

The following table describes what you notice, not a diagnosis. Symptoms need to be checked against the clinical assessment.

What you noticeThe question for the team
Bowel and joints both feel betterAre the agreed inflammation and function targets being met, and what monitoring remains necessary?
Bowel better; joints still troublesomeIs there active joint inflammation, a different pain problem, or a mixture?
Joints better; bowel symptoms persist or returnIs intestinal inflammation active, or is another bowel problem responsible?
Both feel worseIs there loss of disease control, infection, a treatment-delivery problem, or another explanation?

Persistent pain and persistent inflammation are not identical

Pain can continue because inflammation remains active. But tendon overload, an injury, osteoarthritis, reduced muscle strength, or previous structural changes can also cause pain. More than one mechanism can operate in the same person.

In some people, the nervous system becomes more sensitive to pain after prolonged illness. Clinicians may use the term nociplastic pain for altered pain processing that is not adequately explained by ongoing tissue inflammation or a nerve injury. This is real pain. It may coexist with SpA and may need its own treatment; identifying it should not replace an appropriate search for active inflammation.

Sleep disruption, fatigue, anemia, and bowel symptoms can make pain and function worse. A high symptom score therefore needs interpretation. Increasing immune treatment may be useful for confirmed inflammatory activity, but it is unlikely to solve every noninflammatory contributor. Your team should explain which findings support its conclusion and how the remaining symptoms will be addressed. [2][3]

New diarrhea is not automatically an IBD flare

Recurrent bowel symptoms may reflect active IBD, but infection, medication effects, altered bowel function after surgery, or IBS-like symptoms are other possibilities. The likely explanation depends on the details. Blood in the stool, nocturnal symptoms, weight loss, fever, and changes from your usual pattern all deserve attention.

During a suspected flare, the gastroenterology team may check for intestinal infection, including Clostridioides difficile when appropriate. Treating every episode of diarrhea by increasing immune suppression could miss an infection. Conversely, assuming that symptoms are “just IBS” without assessing a meaningful change could miss inflammation. [4]

What tests can help clarify the mismatch?

Blood markers such as CRP can support an assessment of inflammation, but they do not reliably tell the team which organ is responsible. A normal result does not exclude all active SpA or IBD. Examination and the symptom pattern remain important.

Fecal calprotectin helps assess intestinal inflammation; it is not a test of joint activity. Infection and medicines such as NSAIDs can affect the result, sometimes through actual intestinal inflammation. A raised value is not, on its own, a diagnosis of an IBD flare. The team decides whether repeat testing, infection tests, endoscopy, or intestinal imaging would answer the question. Do not stop prescribed medicine merely to prepare for this test unless you receive specific instructions.

Joint examination, ultrasound, or MRI may help when the source of musculoskeletal symptoms remains uncertain. They are selected for a clinical question, not ordered automatically every time pain changes. A scan finding also needs context: not every abnormality explains today’s pain. [1][2][5]

Never worked, partly worked, or stopped working?

These are different histories. Primary nonresponse means the expected benefit was not achieved after an appropriate treatment trial. Secondary loss of response means there was a meaningful initial benefit and then control was lost. A partial response may affect one organ, one symptom, or only part of the day.

Before choosing the next step, the team checks the diagnosis, objective inflammation, treatment duration, dosing, and whether doses were actually delivered. Delays can happen because of infection, travel, cost, pharmacy problems, or misunderstandings. Explain them without embarrassment: the reason can change the solution.

For certain biologics, the gastroenterologist may measure the medicine level and antibodies against it. These tests can sometimes help distinguish inadequate drug exposure from a problem less likely to improve by increasing exposure. They are not useful in the same way for every medicine, and the timing and interpretation matter. Do not alter a dose or its timing to create your own “trough” sample. [6]

Symptoms after a medicine change need a careful timeline

If joint symptoms appear after changing treatment, several explanations are possible. The previous medicine may have been controlling joint inflammation as well as bowel disease. A planned steroid reduction may reveal symptoms that had been suppressed. The new medicine may not cover the same organ pattern, an unrelated problem may have developed, or an adverse reaction may be involved.

Vedolizumab illustrates why timing alone is not enough. It mainly targets the gut. Joint symptoms reported after starting it do not all have the same explanation, and research findings have differed. A small prospective study with repeated clinical and MRI assessments found no new SpA during 24 weeks; that result cannot rule out every uncommon reaction or predict every individual course. [7]

Report the dates of the last old dose, first new dose, steroid changes, and symptom onset. Do not intentionally stop and restart treatment to prove a connection. A coordinated decision can preserve a useful bowel response while addressing the joint problem—or change the plan when the evidence supports it.

Leave with a decision and a follow-up point

Ask: “What is active now? What remains uncertain? What are we changing, and how will we know whether it helped?” Depending on the findings, the next step could be targeted rehabilitation, local treatment, correction of a treatment-delivery problem, adjustment of the current regimen, or a different systemic medicine.

Agree who will contact whom, when results will be reviewed, and what should trigger earlier reassessment. A newly hot swollen joint needs urgent same-day assessment even without fever; a painful red eye or vision change also needs urgent assessment. Do not wait for a routine review of treatment response in either situation. [8][3]

Sources and further reading

  1. ECCO Guidelines on Extraintestinal Manifestations in IBD. 2024.
  2. British Society for Rheumatology guideline on biologic and targeted treatment for axial SpA. 2025.
  3. ACR/SAA/SPARTAN axial SpA guideline: 2026 official recommendation summary.
  4. ECCO Guidelines on Prevention, Diagnosis, and Management of Infections in IBD. 2026.
  5. Randomized trial on the effects of diclofenac and omeprazole on fecal calprotectin. The study does not establish a universal medication-withdrawal interval.
  6. AGA: therapeutic drug monitoring in inflammatory bowel disease.
  7. Rohekar et al. Prospective study of vedolizumab initiation with SpA clinical and imaging assessment. 2024.
  8. SANJO guideline for septic arthritis in native joints. 2023.

Educational information. Individual care depends on the clinical history, examination, investigations and applicable prescribing information.

Chapters in this collection
  1. How Are Bowel, Joint and Spine Inflammation Connected?
  2. Which Symptoms Should I Report?
  3. How Is the Diagnosis Made?
  4. When Do I Need Urgent Help?
  5. Choosing Treatment for Both the Bowel and Joints
  6. Pain Medicines, Infections, Vaccines and Safety Tests
  7. When the Bowel and Joints Respond Differently
  8. Daily Life: Movement, Fatigue, Food and Work
  9. Different Life Stages & Surgery
  10. Preparing for a Shared Care Visit

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: IBD-associated SpondyloarthritisSpondyloarthritis